Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.
about
Neutrophils and Granulocytic MDSC: The Janus God of Cancer ImmunotherapyIgE-based immunotherapy of cancer: challenges and chances.Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes.The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity.Human IgA-binding peptides selected from random peptide libraries: affinity maturation and application in IgA purification.Affinity chromatographic purification of human immunoglobulin a from Chinese hamster ovary cell culture supernatant.Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging.Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) bindingAnti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.Neutrophils in antibody-based immunotherapy of cancer.The role of Fc receptors in HIV prevention and therapy.A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingNaturally occurring structural isomers in serum IgA1 o-glycosylation.Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.Immunoglobulin A: A next generation of therapeutic antibodies?Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.Upstream and downstream processing of recombinant IgA.Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.IgA EGFR antibodies mediate tumour killing in vivo.Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.Design and characterization of a plasmid vector system capable of rapid generation of antibodies of multiple isotypes and specificities.Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Antibody Isotypes for Tumor Immunotherapy.Affinity purification of a framework 1 engineered mouse/human chimeric IgA2 antibody from tobacco.
P2860
Q28069360-70DCE81E-EC57-41C5-8B29-1B38FA5E0E33Q33619979-AE33A256-6D79-4FC3-AD73-EF01A3EA2EAAQ33889191-5890AA10-F927-40DD-8C27-7E7EAE243910Q33891585-573BB7CF-11ED-4585-864E-B4283405439BQ34218284-73062272-D501-41FF-940B-3F64ED2F491FQ34449926-AD012F2A-1865-43EC-8763-842D87066681Q34466477-DFE7B412-A6CF-42A1-A165-084DA32D6A17Q35979595-2484C257-AF9A-4D4A-8C76-2AD5B3D72C38Q36127055-1FC323AB-DD3B-4405-A414-E0F8765A6E83Q36216363-0DC42A7C-B7FE-4227-981D-071780EF30A4Q36366594-AC59F792-F6FD-4FA5-BB1F-06290F6E252DQ37032641-6B78AC5F-A26C-4AED-B585-8E8B0892727FQ37113972-08E51735-E4C7-46B3-A917-D438E462F02DQ37138274-741C47C9-CA51-4852-A313-36EBA5829BF7Q37138332-8BB75457-265E-47F8-8848-45A3AA265CE2Q37352215-394D3137-81BE-410C-A6BF-C06FD3182A8CQ37468539-54E3ABB7-1FF1-4CF7-B481-376777B91189Q37892323-342C9B15-C3E2-401E-B6D3-2EF2DB2FA9CFQ37964490-50647EEB-27FD-4514-A52B-0F4434DA8572Q38254478-CAC365C3-36A7-428F-A12D-09DE11CEEB85Q39027573-F5CDA6C7-C0E3-4BD2-94AE-129605086C31Q39114924-37FF293D-DB5E-4D3B-9204-C87145350F5DQ39358478-79A31FC0-6645-41B8-B748-926460542688Q39699202-E856A983-7986-457B-ABB3-7F0EF4425DDDQ39724220-76EE2A33-BF98-4BE8-8B21-A77538E407DFQ39942174-C53E7212-B58D-47C3-96D9-91E76EFE96ECQ41704272-E99E73BA-2603-48CB-8DA8-D4FA783CEDB6Q42660171-883F085B-56AE-4860-95EA-E9F02C004853Q51593198-AF786423-7DBB-4727-9858-D2C255428AE5
P2860
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Effector mechanisms of recombi ...... dermal growth factor receptor.
@en
Effector mechanisms of recombi ...... dermal growth factor receptor.
@nl
type
label
Effector mechanisms of recombi ...... dermal growth factor receptor.
@en
Effector mechanisms of recombi ...... dermal growth factor receptor.
@nl
prefLabel
Effector mechanisms of recombi ...... dermal growth factor receptor.
@en
Effector mechanisms of recombi ...... dermal growth factor receptor.
@nl
P2093
P1476
Effector mechanisms of recombi ...... dermal growth factor receptor.
@en
P2093
Jan G J van de Winkel
Matthias Peipp
Michael Dechant
Tanja Schneider-Merck
Thomas Beyer
Thomas Valerius
Wencke Weisner
P304
P356
10.4049/JIMMUNOL.179.5.2936
P407
P577
2007-09-01T00:00:00Z